Public health company the US Food and Drug Administration stated on Friday that it has authorised the marketing of the first drug TPOXX (tecovirimat) for treatment of smallpox.
This US FDA approval of TPOXX was awarded to SIGA Technologies Inc under the former's fast track, priority review and orphan drug designations. The drug was developed in conjunction with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
Although the World Health Organisation declared in 1980 that smallpox, a contagious and sometimes fatal infectious disease, was eradicated, there have been longstanding concerns that smallpox could be used as a bioweapon. Complications of smallpox could include encephalitis (inflammation of the brain), corneal ulcerations (an open sore on the clear, front surface of the eye) and blindness.
TPOXX was approved under the US FDA's Animal Rule, which allows efficacy findings from adequate and well-controlled animal studies to support an US FDA approval when it is not feasible or ethical to conduct efficacy trials in humans. The drug's effectiveness against smallpox was based on measuring survival at the end of the studies. More animals treated with TPOXX lived compared to the animals treated with placebo.
Additionally, the safety of the company's TPOXX was evaluated in 359 healthy human volunteers without a smallpox infection. The most frequently reported side effects were headache, nausea and abdominal pain.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial